throbber
Cubicin™
`(daptomycin for injection)
`Rx only
`To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cubicin
`and other antibacterial drugs, Cubicin should be used only to treat or prevent infections caused
`by bacteria.
`
`DESCRIPTION
`
`Cubicin contains daptomycin, a cyclic lipopeptide antibacterial agent derived from the
`fermentation of Streptomyces roseosporus. The chemical name is N-decanoyl-L-tryptophyl-L-
`asparaginyl-L-aspartyl-L-threonylglycyl-L-ornithyl-L-aspartyl-D-alanyl-L-aspartylglycyl-D-
`seryl-threo-3-methyl-L-glutamyl-3-anthraniloyl-L-alanine ε1-lactone. The chemical structure is:
`
`(CH 2 )8 CH 3
`
`O
`
`HN
`
`CONH 2
`O
`
`NH
`
`NH
`
`HN
`
`O
`CO 2 H
`
`NH 2
`
`O
`
`NH 2
`
`O
`
`NH
`
`O
`
`HN
`
`NH
`
`O
`
`O
`
`O
`
`HN
`
`HO 2 C
`
`HN
`
`NH
`
`HO
`
`O
`
`O
`
`O
`
`NH
`
`O
`
`HN
`
`O
`
`NH
`
`HO 2 C
`
`HN
`
`O
`
`O
`
`HO 2 C
`
`The empirical formula is C72H101N17O26; the molecular weight is 1620.67. Cubicin is supplied as
`a sterile, preservative-free, pale yellow to light brown, lyophilized cake containing
`approximately 900 mg/g of daptomycin for intravenous use following reconstitution with 0.9%
`sodium chloride injection. The only inactive ingredient is sodium hydroxide which is used in
`minimal quantities for pH adjustment. Freshly reconstituted solutions of Cubicin range in color
`from pale yellow to light brown.
`
`CLINICAL PHARMACOLOGY
`
`Pharmacokinetics
`
`The mean (SD) pharmacokinetic parameters of daptomycin on Day 7 following the intravenous
`administration of 4 mg/kg, 6 mg/kg, and 8 mg/kg q24h to healthy young adults (mean age 35.8
`years) are summarized in Table 1.
`
`1
`2
`3
`4
`5
`6
`7
`
`8
`
`9
`10
`11
`12
`
`13
`14
`15
`16
`17
`18
`19
`
`20
`
`21
`
`22
`23
`24
`
`1
`
`AMNEAL EX. 1004
`
`

`

`9/12/03
`
`25
`
`Table 1. Mean (SD) Daptomycin Pharmacokinetic Parameters in Healthy Volunteers on Day 7
`
`Dose
`mg/kg
`
`Cmax
`(µg/mL)
`57.8
`(3.0)
`
`98.6
`(12)
`
`133
`(13.5)
`
`*
`
`Tmax
`(h)
`0.8
`(0.5, 1.0)
`
`0.5
`(0.5,1.0)
`
`0.5
`(0.5,1.0)
`
`AUC0-24
`(µg*h/mL)
`494
`(75)
`
`747
`(91)
`
`1130
`(117)
`
`t1/2
`(h)
`8.1
`(1.0)
`
`8.9
`(1.3)
`
`9.0
`(1.2)
`
`4
`(n=6)
`6
`(n=6)
`8
`(n=6)
`*Median (minimum, maximum)
`Cmax = Maximum plasma concentration; Tmax = Time to Cmax; AUC0-24 = Area under concentration-time curve from 0
`to 24 hours; t½ = Terminal elimination half-life; Vd = Apparent volume of distribution; CLT = Systemic clearance;
`CLR = renal clearance; Ae24 = Percent of dose recovered in urine over 24 hours as unchanged daptomycin following
`the first dose.
`Daptomycin pharmacokinetics are nearly linear and time-independent at doses up to 6 mg/kg
`administered once daily for 7 days. Steady-state concentrations are achieved by the third daily
`dose. The mean (SD) steady-state trough concentrations (Days 4 to 8) attained following
`administration of 4, 6, and 8 mg/kg q24h are 5.9 (1.6), 9.4 (2.5) and 14.9 (2.9) µg/mL,
`respectively.
`
`Vd
`(L/kg)
`0.096
`(0.009)
`
`0.104
`(0.013)
`
`0.092
`(0.012)
`
`CLT
`(mL/h/kg)
`8.3
`(1.3)
`
`CLR
`(mL/h/kg)
`4.8 (1.3)
`
`8.1
`(1.0)
`
`7.2
`(0.8)
`
`4.4
`(0.3)
`
`3.7 (0.5)
`
`Ae24
`%
`53.0
`(10.8)
`
`47.4
`(11.5)
`
`52.1
`(5.19)
`
`26
`27
`28
`29
`30
`31
`32
`33
`34
`35
`
`36
`
`37
`38
`39
`40
`41
`
`42
`43
`44
`45
`46
`47
`
`48
`49
`
`50
`
`51
`52
`53
`
`Distribution
`
`Daptomycin is reversibly bound to human plasma proteins, primarily to serum albumin, in a
`concentration-independent manner. The mean serum protein binding of daptomycin was
`approximately 92% in healthy adults after the administration of 4 mg/kg or 6 mg/kg. Serum
`protein binding was not altered as a function of daptomycin concentration, dose, or number of
`doses received.
`
`In clinical studies, mean serum protein binding in subjects with CLCR ≥30 mL/min was
`comparable to that observed in healthy subjects with normal renal function. However, there was
`a trend toward decreasing serum protein binding among subjects with CLCR <30 mL/min
`(87.6%) including hemodialysis patients (85.9%) and CAPD patients (83.5%). The protein
`binding of daptomycin in subjects with hepatic impairment (Child-Pugh B) was similar to
`healthy adult subjects.
`
`The apparent volume of distribution of daptomycin at steady-state in healthy adult subjects was
`approximately 0.09 L/kg.
`
`Metabolism
`
`In vitro studies with human hepatocytes indicate that daptomycin does not inhibit or induce the
`activities of the following human cytochrome (CYP) P450 isoforms: 1A2, 2A6, 2C9, 2C19, 2D6,
`2E1, and 3A4. It is unlikely that daptomycin will inhibit or induce the metabolism of drugs
`
`2
`
`AMNEAL EX. 1004
`
`

`

`9/12/03
`
`metabolized by the CYP P450 system. It is unknown whether daptomycin is a substrate of the
`CYP P450 system.
`
`In five healthy young adults after infusion of radiolabeled 14C-daptomycin, the plasma total
`radioactivity was similar to the concentration determined by microbiological assay. Inactive
`metabolites of daptomycin have been detected in the urine, as determined by the difference in
`total radiolabeled concentrations and microbiologically active concentrations. The site of
`metabolism has not been identified.
`
`Excretion
`
`Daptomycin is excreted primarily by the kidney. In a mass balance study of five healthy subjects
`using radiolabeled daptomycin, approximately 78% of the administered dose was recovered from
`urine based on total radioactivity (approximately 52% of the dose based on microbiologically
`active concentrations) and 5.7% of the dose was recovered from feces (collected for up to nine
`days) based on total radioactivity.
`
`Because renal excretion is the primary route of elimination, dosage adjustment is necessary in
`patients with severe renal insufficiency (CLCR < 30 mL/min) (see DOSAGE AND
`ADMINISTRATION).
`
`Special Populations
`
`Renal Insufficiency
`
`Population derived pharmacokinetic parameters were determined for patients with skin and skin
`structure infections and healthy non-infected subjects with varying degrees of renal function
`(n=282). Following the administration of a single 4 mg/kg IV dose of daptomycin, the plasma
`clearance (CLT) was reduced and the systemic exposure (AUC0-∞) was increased with decreasing
`renal function (see Table 2). The mean AUC0-∞ was not markedly different for subjects and
`patients with CLCR 30-80 mL/min as compared to those with normal renal function (CLCR
`>80mL/min). The mean AUC0-∞ values for subjects and patients with CLCR <30 mL/min and
`hemodialysis (dosed post dialysis)/CAPD subjects were approximately 2- and 3-times higher,
`respectively, than the values in individuals with normal renal function. The mean Cmax ranged
`from 59.6 µg/mL to 69.6 µg/mL in subjects with CLCR ≥ 30 mL/min while those with CLCR <30
`mL/min ranged from 41.1 µg/mL to 57.7 µg/mL. In 11 non-infected adult subjects undergoing
`dialysis, approximately 15% and 11% of the administered dose was removed by 4 hours of
`hemodialysis and 48 hours of CAPD, respectively. The recommended dosing regimen is 4 mg/kg
`once every 24 hours for patients with CLCR ≥ 30 mL/min and 4 mg/kg once every 48 hours for
`CLCR <30 mL/min, including those on hemodialysis and CAPD. Daptomycin should be
`administered following the completion of hemodialysis on hemodialysis days (see DOSAGE
`AND ADMINISTRATION).
`
`54
`55
`
`56
`57
`58
`59
`60
`
`61
`
`62
`63
`64
`65
`66
`
`67
`68
`69
`
`70
`
`71
`
`72
`73
`74
`75
`76
`77
`78
`79
`80
`81
`82
`83
`84
`85
`86
`87
`88
`
`3
`
`AMNEAL EX. 1004
`
`

`

`9/12/03
`
`89
`90
`91
`
`Table 2. Mean (SD) Daptomycin Population Pharmacokinetic Parameters Following a Single 30-Minute
`Intravenous Infusion of 4 mg/kg to Infected Patients and Non-Infected Subjects with Varying Degrees of
`Renal Function
`
`Renal Function
`
`AUC0-∞
`(µg*h/mL)
`417 (155)
`
`t1/2
`(h)
`9.39 (4.74)
`
`Vss
`(L/kg)
`0.13 (0.05)
`
`CLT
`(mL/h/kg)
`10.9 (4.0)
`
`466 (177)
`
`10.75 (8.36)
`
`0.12 (0.05)
`
`9.9 (4.0)
`
`Normal
`(CLCR >80 mL/min) (N=165)
`Mild Renal Impairment
`(CLCR 50-80 mL/min) (N=64)
`Moderate Renal Impairment
`(CLCR 30-<50 mL/min) (N=24)
`Severe Renal Impairment
`(CLCR <30 mL/min) (N=8)
`3.7 (1.9)
`0.15 (0.04)
`29.81 (6.13)
`1244 (374)
` Hemodialysis and CAPD (N=21)
`Note: CLCR = Creatinine clearance estimated using the Cockroft-Gault equation with actual body weight.
`Hepatic Insufficiency
`
`560 (258)
`
`925 (467)
`
`14.70
`(10.50)
`
`27.83
`(14.85)
`
`0.15 (0.06)
`
`8.5 (3.4)
`
`0.20 (0.15)
`
`5.9 (3.9)
`
`The pharmacokinetics of daptomycin were evaluated in 10 subjects with moderate hepatic
`impairment (Child-Pugh Class B) and compared with healthy volunteers (n=9) matched for
`gender, age and weight. The pharmacokinetics of daptomycin were not altered in subjects with
`moderate hepatic impairment. No dosage adjustment is warranted when administering
`daptomycin to patients with mild to moderate hepatic impairment. The pharmacokinetics of
`daptomycin in patients with severe hepatic insufficiency have not been evaluated.
`
`Gender
`
`No clinically significant gender-related differences in daptomycin pharmacokinetics have been
`observed between healthy male and female subjects. No dosage adjustment is warranted based
`on gender when administering daptomycin.
`
`Geriatric
`
`The pharmacokinetics of daptomycin were evaluated in 12 healthy elderly subjects (≥ 75 years of
`age) and 11 healthy young matched controls (18-30 years of age). Following administration of a
`single intravenous 4 mg/kg dose, the mean total clearance of daptomycin was reduced
`approximately 35% and the mean AUC0-∞ increased approximately 58% in elderly subjects
`compared to young healthy subjects. There were no differences in Cmax. No dosage adjustment is
`warranted for elderly patients with normal (for age) renal function.
`
` Obesity
`
`The pharmacokinetics of daptomycin were evaluated in six moderately obese (Body Mass Index
`[BMI] 25-39.9 kg/m2) and six extremely obese (BMI ≥40 kg/m2) subjects and controls matched
`for age, sex, and renal function. Following administration of a single intravenous 4 mg/kg dose
`
`4
`
`92
`93
`
`94
`95
`96
`97
`98
`99
`
`100
`
`101
`102
`103
`
`104
`
`105
`106
`107
`108
`109
`110
`
`111
`
`112
`113
`114
`
`AMNEAL EX. 1004
`
`

`

`9/12/03
`
`115
`116
`117
`118
`119
`120
`
`121
`
`122
`123
`
`124
`
`125
`126
`
`127
`
`128
`129
`130
`131
`132
`
`133
`
`134
`135
`136
`137
`138
`139
`140
`
`141
`
`142
`143
`144
`145
`
`146
`
`147
`148
`149
`150
`
`based on total body weight, the plasma clearance of daptomycin increased approximately 18% in
`moderately obese subjects and 46% in extremely obese subjects compared with non-obese
`controls. The AUC0-∞ of daptomycin increased approximately 30% in moderately obese and 31%
`in extremely obese subjects compared with non-obese controls. The differences were most likely
`due to differences in the renal clearance of daptomycin. No dosage adjustment of daptomycin is
`warranted in obese subjects.
`
`Pediatric
`
`The pharmacokinetics of daptomycin in pediatric populations (<18 years of age) have not been
`established.
`
`Drug-Drug Interactions
`
`Drug-drug interaction studies were performed with daptomycin and other drugs that are likely to
`either be co-administered or associated with overlapping toxicity.
`
`Aztreonam
`
`In a study in which 15 healthy adult subjects received a single dose of daptomycin IV 6 mg/kg,
`aztreonam 1,000 mg IV, and both in combination, the Cmax and AUC0-∞ of daptomycin were not
`significantly altered by aztreonam; the Cmax and AUC0-∞ of aztreonam were also not significantly
`altered by daptomycin. No dosage adjustment of either antibiotic is warranted when co-
`administered.
`
`Tobramycin
`
`In a study in which 6 healthy adult males received a single dose of daptomycin IV 2 mg/kg,
`tobramycin IV 1 mg/kg, and both in combination, the mean Cmax and AUC0-∞ of daptomycin
`increased 12.7% and 8.7%, respectively, when administered with tobramycin. The mean Cmax
`and AUC0-∞ of tobramycin decreased 10.7% and 6.6%, respectively, when administered with
`daptomycin. None of these differences was statistically significant. The interaction between
`daptomycin and tobramycin with a clinical dose of daptomycin (4 mg/kg) is unknown. Caution is
`warranted when daptomycin is co-administered with tobramycin.
`
`Warfarin
`
`In 16 healthy subjects, concomitant administration of daptomycin 6 mg/kg once daily for 5 days
`followed by a single oral dose of warfarin (25 mg) had no significant effect on the
`pharmacokinetics of either drug and did not significantly alter the INR (International Normalized
`Ratio). (see PRECAUTIONS, Drug Interactions)
`
`Simvastatin
`
`In 20 healthy subjects on a stable daily dose of simvastatin 40 mg, administration of daptomycin
`IV 4 mg/kg once daily for 14 days (n=10) was not associated with a higher incidence of adverse
`events than subjects receiving placebo once daily (n=10) (see PRECAUTIONS, Drug
`Interactions).
`
`5
`
`AMNEAL EX. 1004
`
`

`

`151
`
`152
`153
`154
`155
`
`156
`
`157
`158
`159
`160
`161
`162
`
`163
`164
`165
`
`166
`167
`168
`169
`
`170
`
`171
`172
`173
`174
`
`175
`
`176
`177
`178
`179
`180
`181
`182
`183
`184
`185
`
`9/12/03
`
`Probenecid
`
`Concomitant administration of probenecid (500 mg four times daily) and a single dose of
`daptomycin IV 4 mg/kg did not significantly alter the Cmax and AUC0-∞ of daptomycin. No
`dosage adjustment of daptomycin is warranted when daptomycin is co-administered with
`probenecid.
`
`MICROBIOLOGY
`
`Daptomycin is an antibacterial agent of a new class of antibiotics, the cyclic lipopeptides.
`Daptomycin is a natural product which has clinical utility in the treatment of infections caused
`by aerobic Gram-positive bacteria. The in vitro spectrum of activity of daptomycin encompasses
`most clinically relevant Gram-positive pathogenic bacteria. Daptomycin retains potency against
`antibiotic resistant Gram-positive bacteria including isolates resistant to methicillin, vancomycin,
`and linezolid.
`
`Daptomycin exhibits rapid, concentration-dependent bactericidal activity against Gram-positive
`organisms in vitro. This has been demonstrated both by time-kill curves and by MBC/MIC
`ratios using broth dilution methodology.
`
`In vitro studies have demonstrated additive or indifferent interactions of daptomycin with other
`antibiotics. Antagonism, as determined by kill curve studies, has not been observed. In vitro
`synergistic interactions occurred with aminoglycosides and β-lactam antibiotics against some
`isolates of staphylococci and enterococci, including some MRSA isolates.
`
`Mechanism of Action
`
`The mechanism of action of daptomycin is distinct from any other antibiotic. Daptomycin binds
`to bacterial membranes and causes a rapid depolarization of membrane potential. The loss of
`membrane potential leads to inhibition of protein, DNA, and RNA synthesis, which results in
`bacterial cell death.
`
`Resistance
`
`Mechanisms of Resistance
`At this time, no mechanism of resistance to daptomycin has been identified.
`Currently, there are no known transferable elements that confer resistance to
`daptomycin.
`Cross Resistance
`Cross-resistance has not been observed with any other class of antibiotic.
`
`Other
`
`The emergence of resistance to daptomycin occurred in 2 of more than 1000
`(<0.2%) infected subjects across the entire set of Phase 2 and 3 clinical trials. In
`one case, a resistant S. aureus was isolated from a patient in a Phase 2 study who
`
`6
`
`AMNEAL EX. 1004
`
`

`

`186
`187
`188
`189
`190
`191
`
`192
`193
`194
`195
`196
`197
`198
`199
`200
`201
`202
`
`203
`204
`205
`206
`207
`208
`209
`
`210
`211
`212
`213
`
`214
`
`215
`216
`217
`218
`219
`220
`
`221
`
`222
`223
`
`9/12/03
`
`received daptomycin at less than the protocol-specified dose for the initial 5 days
`of therapy. In the second case, a resistant E. faecalis was isolated from a patient
`with an infected chronic decubitus ulcer enrolled in a salvage trial.
`Daptomycin has been shown to be active against most isolates of the following microorganisms
`both in vitro and in clinical infections, as described in the INDICATIONS AND USAGE
`section.
`
`Aerobic and facultative Gram-positive microorganisms:
`Enterococcus faecalis (vancomycin-susceptible strains only)
`Staphylococcus aureus (including methicillin-resistant strains)
`Streptococcus agalactiae
`Streptococcus dysgalactiae subsp. equisimilis
`Streptococcus pyogenes
`The following in vitro data are available, but their clinical significance is unknown. Greater than
`90% of the following microorganisms demonstrate an in vitro MIC less than or equal to the
`susceptible breakpoint for daptomycin versus the bacterial genus. The efficacy of daptomycin in
`treating clinical infections due to these microorganisms has not been established in adequate and
`well-controlled clinical trials.
`
`Aerobic and facultative Gram-positive microorganisms:
`Corynebacterium jeikeium
`Enterococcus faecalis (vancomycin-resistant strains)
`Enterococcus faecium (including vancomycin-resistant strains)
`Staphylococcus epidermidis (including methicillin-resistant strains)
`Staphylococcus haemolyticus
`Susceptibility Testing Methods
`
`Susceptibility testing by dilution methods requires the use of daptomycin susceptibility powder.
`The testing also requires presence of physiological levels of free calcium ions (50 mg/L calcium
`chloride) in Mueller-Hinton broth medium and a minimum of 28 mg/L calcium chloride in
`Mueller-Hinton agar medium.
`
`Dilution technique
`
`Quantitative methods are used to determine antimicrobial MICs. These MICs provide estimates
`of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined
`using a standardized procedure2, 3. Standardized procedures are based on a dilution method
`(broth or agar) or equivalent with standardized inoculum concentrations and standardized
`concentrations of daptomycin powder. The MIC values should be interpreted according to the
`criteria in Table 3.
`
`Diffusion technique
`
`Quantitative methods that require measurement of zone diameters also provide reproducible
`estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized
`
`7
`
`AMNEAL EX. 1004
`
`

`

`224
`225
`226
`
`227
`
`228
`229
`230
`231
`232
`233
`234
`235
`236
`237
`238
`239
`240
`241
`242
`
`243
`
`244
`245
`246
`247
`248
`249
`
`9/12/03
`
`procedure requires the use of standardized inoculum concentrations1, 3. This procedure uses
`paper disks impregnated with 30 µg of daptomycin to test the susceptibility of microorganisms to
`daptomycin. The disk diffusion interpretive criteria are provided in Table 3.
`
`Table 3. Susceptibility Interpretive Criteria for Daptomycin
`
`Pathogen
`
`Minimal inhibitory
`concentration (µg/mL)a
`
`Staphylococcus aureus
`(methicillin-susceptible and
`methicillin-resistant)
`Streptococcus pyogenes,
`Streptococcus agalactiae, and
`Streptococcus dysgalactiae
`subsp. equisimilis
`Enterococcus faecalis
`(vancomycin–susceptible
`only)
`
`S
`≤1
`
`≤1
`
`≤4
`
`Disk diffusion zone
`Diameter (mm)b
`S
`I
`(c)
`≥16
`
`≥16
`
`(c)
`
`R
`(c)
`
`(c)
`
`I
`(c)
`
`(c)
`
`R
`(c)
`
`(c)
`
`(c)
`
`(c)
`
`≥11
`
`(c)
`
`(c)
`
`a. The MIC interpretive criteria for S. aureus and E. faecalis are applicable only to tests performed by broth
`microdilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L; the MIC interpretive
`criteria for Streptococcus spp. other than S. pneumoniae are applicable only to tests performed by broth
`microdilution using Mueller-Hinton broth adjusted to a calcium content of 50 mg/L, supplemented with 2 to 5%
`lysed horse blood, inoculated with a direct colony suspension and incubated in ambient air at 35ºC for 20 to 24
`hours.
`b. The zone diameter interpretive criteria for Streptococcus spp. other than S. pneumoniae are applicable only to
`tests performed using Mueller-Hinton agar supplemented with 5% defibrinated sheep blood and incubated in
`5% CO2 at 35ºC for 20 to 24 hours.
`c. The current absence of data on daptomycin resistant strains precludes defining any categories other than
`“Susceptible”. Strains yielding test results suggestive of a “non-susceptible” category should be retested, and if
`the result is confirmed, the isolate should be submitted to a reference laboratory for further testing.
`A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial
`compound in the blood reaches the concentrations usually achievable.
`
`Quality Control
`
`Standardized susceptibility test procedures require the use of quality control microorganisms to
`control the technical aspects of the procedures. Standard daptomycin powder should provide the
`range of values noted in Table 4. Quality control microorganisms are specific strains of
`organisms with intrinsic biological properties relating to resistance mechanisms and their genetic
`expression within bacteria; the specific strains used for microbiological quality control are not
`clinically significant.
`
`8
`
`AMNEAL EX. 1004
`
`

`

`9/12/03
`
`250
`251
`
`Table 4. Acceptable Quality Control Ranges for Daptomycin to be Used in Validation of Susceptibility Test
`Results
`
`QC Strain
`
`Enterococcus faecalis
`ATCC 29212
`Staphylococcus aureus
`ATCC 29213
`Staphylococcus aureus
`ATCC 25923
`Streptococcus pneumoniae
`ATCC 49619 c
`
`Acceptable Quality Control Ranges
`Minimum Inhibitory
`Disk Diffusion
`Concentration
`(Zone Diameters in mm) b
`(MIC in µg/mL)a
`1-8
`
`Not applicable
`
`0.25-1
`
`Not applicable
`
`Not applicable
`
`0.06-0.5 d
`
`18-23
`
`19-26 e
`
`252
`253
`254
`255
`256
`257
`258
`259
`260
`261
`262
`263
`264
`
`265
`266
`267
`268
`269
`270
`271
`
`272
`
`273
`274
`275
`276
`
`277
`278
`
`a. Quality control ranges reflect MICs obtained when Mueller-Hinton broth is supplemented with calcium to a
`final concentration of 50 mg/L.
`b. Some lots of Mueller-Hinton agar are deficient in calcium and give small zone diameters.
`c. This organism may be used for validation of susceptibility test results when testing Streptococcus spp. other
`than S. pneumoniae.
`d. This quality control range for S. pneumoniae is applicable only to tests performed by broth microdilution using
`cation adjusted Mueller-Hinton broth with 2-5% lysed horse blood inoculated with a direct colony suspension
`and incubated in ambient air at 35ºC for 20 to 24 hours.
`e. This quality control zone diameter range is applicable only to tests performed using Mueller-Hinton agar
`supplemented with 5% defibrinated sheep blood inoculated with a direct colony suspension and incubated in
`5% CO2 at 35ºC for 20 to 24 hours.
`INDICATIONS AND USAGE
`
`Cubicin (daptomycin for injection) is indicated for the treatment of complicated skin and skin
`structure infections caused by susceptible strains of the following Gram-positive microorganisms
`(see also DOSAGE AND ADMINISTRATION): Staphylococcus aureus (including
`methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus
`dysgalactiae subsp. equisimilis and Enterococcus faecalis (vancomycin-susceptible strains only).
`Combination therapy may be clinically indicated if the documented or presumed pathogens
`include Gram-negative or anaerobic organisms. (see CLINICAL STUDIES).
`
`Daptomycin is not indicated for the treatment of pneumonia.
`
`Appropriate specimens for microbiological examination should be obtained in order to isolate
`and identify the causative pathogens and to determine their susceptibility to daptomycin.
`Empiric therapy may be initiated while awaiting test results. Antimicrobial therapy should be
`adjusted as needed based upon test results.
`
`To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cubicin
`and other antibacterial drugs, Cubicin should be used only to treat or prevent infections that are
`
`9
`
`AMNEAL EX. 1004
`
`

`

`279
`280
`281
`282
`
`283
`
`284
`
`285
`
`286
`287
`288
`289
`
`290
`291
`292
`
`293
`294
`295
`296
`297
`
`298
`
`299
`
`300
`301
`
`302
`303
`304
`
`305
`
`306
`307
`308
`309
`310
`
`311
`312
`313
`
`9/12/03
`
`proven or strongly suspected to be caused by susceptible bacteria. When culture and
`susceptibility information are available, they should be considered in selecting or modifying
`antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns
`may contribute to the empiric selection of therapy.
`
`CONTRAINDICATIONS
`
`Cubicin is contraindicated in patients with known hypersensitivity to daptomycin.
`
`WARNINGS
`
`Pseudomembranous colitis has been reported with nearly all antibacterial agents, including
`daptomycin, and may range in severity from mild to life-threatening. Therefore it is important to
`consider this diagnosis in patients who present with diarrhea subsequent to the administration of
`any antibacterial agent.
`
`Treatment with antibacterial agents alters the normal flora of the colon and may permit
`overgrowth of clostridia. Studies indicated that a toxin produced by Clostridium difficile is a
`primary cause of “antibiotic-associated colitis.”
`
`If a diagnosis of pseudomembranous colitis has been established, appropriate therapeutic
`measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug
`discontinuation alone. In moderate to severe cases, consideration should be given to
`management with fluids and electrolytes, protein supplementation, and treatment with an
`antibacterial agent clinically effective against C. difficile.
`
`PRECAUTIONS
`
`General
`
`The use of antibiotics may promote the overgrowth of nonsusceptible organisms. Should
`superinfection occur during therapy, appropriate measures should be taken.
`
`Prescribing Cubicin in the absence of a proven or strongly suspected bacterial infection or a
`prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the
`development of drug-resistant bacteria.
`
`Skeletal Muscle
`
`In Phase 3 complicated skin and skin structure infection (cSSSI) trials, elevations in serum
`creatine phosphokinase (CPK) were reported as clinical adverse events in 15/534 (2.8%)
`daptomycin-treated patients, compared to 10/558 (1.8%) comparator-treated patients. Skeletal
`muscle effects associated with daptomycin were observed in animals (see ANIMAL
`PHARMACOLOGY).
`
`Patients receiving Cubicin should be monitored for the development of muscle pain or weakness,
`particularly of the distal extremities. CPK levels should be monitored weekly in patients who
`receive Cubicin. Patients who develop unexplained elevations in CPK while receiving
`
`10
`
`AMNEAL EX. 1004
`
`

`

`9/12/03
`
`314
`315
`316
`317
`318
`319
`
`320
`321
`322
`323
`324
`325
`326
`327
`328
`329
`330
`331
`332
`333
`334
`335
`
`336
`
`337
`338
`339
`340
`341
`342
`343
`
`344
`
`345
`346
`347
`348
`349
`350
`351
`
`daptomycin should be monitored more frequently. Among patients with abnormal CPK (>500
`U/L) at baseline, 2/19 (10.5%) treated with Cubicin and 4/24 (16.7%) treated with comparator
`developed further increases in CPK while on therapy. In this same population, no patients
`developed myopathy. Daptomycin-treated patients with baseline CPK >500 U/L (n=19) did not
`experience an increased incidence of CPK elevations or myopathy relative to those treated with
`comparator (n=24).
`
`Cubicin should be discontinued in patients with unexplained signs and symptoms of myopathy in
`conjunction with CPK elevation >1000 U/L (~5X ULN), or in patients without reported
`symptoms who have marked elevations in CPK (>10X ULN). In addition, consideration should
`be given to temporarily suspending agents associated with rhabdomyolysis, such as HMG-CoA
`reductase inhibitors, in patients receiving Cubicin.
`In a small number of patients in Phase 1 and Phase 2 studies, administration of Cubicin was
`associated with decreases in nerve conduction velocity and with adverse events (e.g.,
`paresthesias, Bell’s palsy) possibly reflective of peripheral or cranial neuropathy. Nerve
`conduction deficits were also detected in a similar number of comparator subjects in these
`studies. In Phase 3 cSSSI and CAP studies 7/989 (0.7%) daptomycin-treated patients and 7/1018
`(0.7%) comparator-treated patients experienced paresthesias. New or worsening peripheral
`neuropathy was not diagnosed in any of these patients. In animals, effects of daptomycin on
`peripheral nerve were observed (see ANIMAL PHARMACOLOGY). Therefore, physicians
`should be alert to the possibility of signs and symptoms of neuropathy in patients receiving
`Cubicin.
`Drug Interactions
`
`Warfarin
`
`Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and
`warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either
`drug and the INR was not significantly altered. As experience with the concomitant
`administration of daptomycin and warfarin is limited to volunteer studies, anticoagulant activity
`in patients receiving daptomycin and warfarin should be monitored for the first several days after
`initiating therapy with Cubicin (see CLINICAL PHARMACOLOGY, Drug-Drug
`Interactions).
`
`HMG CoA Reductase Inhibitors
`
`Inhibitors of HMG-CoA reductase may cause myopathy, which is manifested as muscle pain or
`weakness associated with elevated levels of CPK. There were no reports of skeletal myopathy in
`a placebo-controlled Phase I trial in which 10 healthy subjects on stable simvastatin therapy were
`treated concurrently with daptomycin (4 mg/kg once every 24 hours) for 14 days. Experience
`with co-administration of HMG-CoA reductase inhibitors and Cubicin in patients is limited,
`therefore, consideration should be given to temporarily suspending use of HMG-CoA reductase
`inhibitors in patients receiving Cubicin.
`
`11
`
`AMNEAL EX. 1004
`
`

`

`9/12/03
`
`Drug-Laboratory Test Interactions
`
`There are no reported drug-laboratory test interactions.
`
`Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`Long-term carcinogenicity studies in animals have not been conducted to evaluate the
`carcinogenic potential of daptomycin. However, neither mutagenic nor clastogenic potential was
`found in a battery of genotoxicity tests, including the Ames assay, a mammalian cell gene
`mutation assay, a test for chromosomal aberrations in Chinese hamster ovary cells, an in vivo
`micronucleus assay, an in vitro DNA repair assay, and an in vivo sister chromatid exchange
`assay in Chinese hamsters.
`
`Daptomycin did not affect the fertility or reproductive performance of male and female rats when
`administered intravenously at doses up to 150 mg/kg/day, which is approximately 9 times the
`estimated human exposure level based upon AUCs.
`
`Pregnancy
`
`Teratogenic effects: Pregnancy Category B
`
`Reproductive and teratology studies performed in rats and rabbits at doses of up to 75 mg/kg, 3
`and 6 times the human dose respectively on a body surface area basis, have revealed no evidence
`of harm to the fetus due to Cubicin. There are, however, no adequate and well controlled studies
`in pregnant women. Because animal reproduction studies are not always predictive of human
`response, this drug should be used during pregnancy only if clearly needed.
`
`Nursing Mothers
`
`It is not known if daptomycin is excreted in human milk. Caution should be exercised when
`Cubicin is administered to nursing women.
`
`Pediatric Use
`
`Safety and efficacy of Cubicin in patients under the age of 18 have not been established.
`
`Geriatric Use
`
`Of the 534 patients treated with Cubicin in Phase 3 controlled clinical trials of complicated skin
`and skin structure infection, 27.0% were 65 years of age or older and 12.4% were 75 years or
`older. In the two Phase 3 clinical studies in patients with cSSSI, lower clinical success rates were
`seen in patients ≥65 years of age compared to those <65 years of age. In addition, treatment-
`emergent adverse events were more common in patients ≥65 years old than in patients <65 years
`of age in both cSSSI studies.
`
`352
`
`353
`
`354
`
`355
`356
`357
`358
`359
`360
`
`361
`362
`363
`
`364
`
`365
`
`366
`367
`368
`369
`370
`
`371
`
`372
`373
`
`374
`
`375
`
`376
`
`377
`378
`379
`380
`381
`382
`
`12
`
`AMNEAL EX. 1004
`
`

`

`9/12/03
`
`ANIMAL PHARMACOLOGY
`
`In animals, daptomycin administration has been associated with effects on skeletal muscle with
`no changes in cardiac or smooth muscle. Skeletal muscle effects were characterized by
`degenerative/regenerative changes and variable elevations in CPK. No fibrosis or
`rhabdomyolysis was evident in repeat dose studies up to the highest doses tested in rats (150
`mg/kg/day) and dogs (100 mg/kg/day). The degree of skeletal myopathy showed no increase
`when treatment was extended from 1 month to up to 6 months. Severity was dose dependent. All
`muscle effects, including microscopic changes, were fully reversible within 30 days following
`cessation of dosing.
`
`In adult animals, effects on peripheral nerve (characterized by axonal degeneration and
`frequently accompanied by significant losses of patellar reflex, gag reflex and pain perception)
`were observed at doses higher than those associated with skeletal myopathy. Deficits in the dogs'
`patellar reflexes were seen within 2 weeks of the start of treatment at 40 mg/kg (3.5 times the
`human AUC), with some clinical improvement noted within 2 weeks of the cessation of dosing.
`However, at 75 mg/kg daily for 1 month, 7/8 dogs failed to regain full patellar reflex responses
`within the duration of a 3 month recovery period. In a separate study in dogs receiving doses of
`75 and 100 mg/kg/day for 2 weeks, minimal residual histological changes were noted at 6
`months after cessation of dosing. However, recovery of peripheral nerve function was evident.
`
`Tissue distribution studies in rats have shown that daptomycin is retained in the kidney, but does
`not appear to penetrate across the blood-brain barrier following single and multiple doses.
`
`ADVERSE REAC

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket